34 results about "Factor XII" patented technology

A hemostatic composition which comprises at least one procoagulant metal ion, such as silver (I) or mercury (II), and at least one procoagulant biopolymer, such as collagen, thrombin, prothrombin, fibrin, fibrinogen, heparinase, Factor VIIa, Factor VIII, Factor IXa, Factor Xa, Factor XII, von Willebrand Factor, a selectin, a procoagulant venom, a plasminogen activator inhibitor, glycoprotein IIb-IIIa, a protease, or plasma. The composition in the form of a paste, dough, glue, liquid, lyophilized powder or foam, may be provided, for application to a wound. A hemostatic device is also described which comprises a hemostatic composition as described above. The device may be in the form of, for example, a plug, bandage, gauze, cloth, tampon, membrane or sponge. Methods are also provided for prophylaxis or treatment of bleeding at a site by application to the site of the composition or device as described.

RNA interference (RNAi) triggers for inhibiting the expression of Factor XII (F12) gene through the mechanism of RNA interference are described. Pharmaceutical compositions comprising one or more F12RNAi triggers together with one or more excipients capable of delivering the RNAi trigger(s) to a liver cell in vivo are also described. Delivery of the F12 RNAi trigger(s) to liver cells in vivo provides for inhibition of F12 gene expression and treatment of angioedema, including hereditary angioedema (HAE) and venous thromboembolism (VTE), and diseases associated with angioedema.

The present invention relates to methods of introducing one or more cysteine residues into a polypeptide which permit the stabilization of the polypeptide by formation of at least one bond, preferably a disulfide bond, between different domains of the polypeptide. The invention also relates to polypeptides containing such introduced cysteine residue(s), nucleic acids encoding such polypeptides and pharmaceutical compositions comprising such polypeptides or nucleic acids. The invention also relates to vectors, viral particles and host cells containing such nucleic acids, and methods of using them to produce the polypeptides of the invention. Exemplified polypeptides include plasma proteins, including hepatocyte growth factor activator and plasma hyaluronin binding protein, as well as blood coagulation factors, such as Factor VIII, Factor V, Factor XII and prothrombin.

The invention discloses a target spot for treating septicemia, belonging to the technical field of treatment of septicemia. The target spot is Factor XI or Factor XII, and can block a Factor XI or Factor XII expression in a septicemia patient body so as to treat septicemia. According to the invention, an antibody-14E11for blocking the Factor XI expression is a novel medicine for treating septicemia after the APC (aspirin compound tablet), and due to the special position of Factor XI on a clotting cascade chain, the occurrence rate of side effects should be obviously lower than that of the APC.

The invention relates to inhibitory anti-factor XII / FXIIa antibodies and methods of their use.

This invention is directed to a vector which comprises a promoter operably linked to a nucleic acid sequence encoding the human C1 esterase inhibitor or Factor XII. The invention is also directed to a composition comprising the vector and a method of using the vector to treat or prevent hereditary angioedema.

The invention relates to inhibitory anti-factor XII / FXIIa antibodies and methods of their use.

The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or theKininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and / or a KNG1 gene, and methods of treating subjects having an hereditary angioedema(HAE) and / or a contact activation pathway-associated disorder.

The present invention relates to methods of introducing one or more cysteine residues into a polypeptide which permit the stabilization of the polypeptide by formation of at least one bond, preferably a disulfide bond, between different domains of the polypeptide. The invention also relates to polypeptides containing such introduced cysteine residue(s), nucleic acids encoding such polypeptides and pharmaceutical compositions comprising such polypeptides or nucleic acids. The invention also relates to vectors, viral particles and host cells containing such nucleic acids, and methods of using them to produce the polypeptides of the invention. Exemplified polypeptides include plasma proteins, including hepatocyte growth factor activator and plasma hyaluronin binding protein, as well as blood coagulation factors, such as Factor VIII, Factor V, Factor XII and prothrombin.

The present invention relates to methods of use of RNAi agents, e.g., double stranded RNAi agents, targeting a Factor XII (Hageman Factor (F12) gene, for treating subjects having a contact activation pathway-associated disease, such as a thrombophilia or hereditary angioedema (HAE), methods for preventing at least one symptom in a subject having a contact activation pathway-associated disease, such as a thrombus formation or an angioedema attack, and RNAi agents targeting an F12 gene, for use in the methods of the invention.

The invention provides assay methods of detecting plasma protease CI inhibitor (Cl-INH) that binds plasma kallikrein, Factor XII, or both, and uses thereof for identifying subjects at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment.

The invention relates to evaluation, assays and treatment of PKAL-mediated disorders. The invention provides assay methods of detecting plasma protease CI inhibitor (Cl-INH) that binds plasma kallikrein, factor XII, or both, and uses thereof for identifying subjects at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment.

This invention is directed to a vector which comprises a promoter operably linked to a nucleic acid sequence encoding the human C1 esterase inhibitor or Factor XII. The invention is also directed to a composition comprising the vector and a method of using the vector to treat or prevent hereditary angioedema.

The present invention relates to low molecular weight sulfated galactans, obtained from algae, particularly genus Botryocladia, preferably species Botryocladia occidentallis, which have no effect on the factor XII activation of the clotting cascade, having antithrombotic heparinoid activity. The present invention also refers to a pharmaceutical composition comprising said sulfated galactans and the use thereof, as heparin substitute, in the treatment or prophylaxis of arterial or venous thrombosis in humans and animals. Furthermore, the present invention provides a method of extraction of the said sulfated galactans.

The present invention relates to modified serpins for use in the treatment of bradykinin-mediated diseases. The modified serine protease inhibitors (serpins) have mutations in one or more of the P4, P3, P2, P1 and P1′ residues of their reactive center loop, which mutations increase the serpin's inhibition of plasma kallikrein (PK) as compared to the corresponding unmodified serpin. The mutations in the modified serpins of the invention further ensure that serpins display substantially no inhibition of at least thrombin and activated protein C. A modified serpin of the invention further preferably shows increased inhibition of at least one of an active form of Factor XII (FXII) and plasmin as compared to the corresponding unmodified serpin, and, preferably, the serpin inhibits at least one of an active form of FXII and PK stronger than they are inhibited by C1 esterase inhibitor. Preferably the modified serpin is a modified α1-antitrypsin. The invention further pertains to nucleic acid molecule encoding the modified serpins of the invention, e.g. a gene therapy vector, and to pharmaceutical compositions comprising the modified serpins of the invention or such gene therapy vectors.

The present invention provides monoclonal antibodies that bind to the Factor XII (FXII) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to FXII and to the activated form of FXII (FXIIa). In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing FXII activity, thus providing a means of treating or preventing a disease, disorder or condition associated with thrombosis in humans.

The invention relates to compounds of formula (I) and methods of treatment by using the compounds. The invention also relates to processes and methods for producing the compounds of the invention. Thecompounds of the invention are modulators of Factor XII (e.g. Factor XIIa). In particular, the compounds are inhibitors of Factor XIIa and may be useful as anticoagulants.

This invention relates to compounds of formula (I). The compounds of formula (I) are modulators of Factor XII, specifically Factor XIIa. The compounds are inhibitors of Factor XIIa and may be useful as anticoagulants. The compounds of formula (I) may be used in methods of treatment (or prevention) of blood disorders related to bleeding or coagulation.

RNA interference (RNAi) initiators for inhibiting the expression of Factor XII (F12) gene by the RNA interference mechanism are disclosed. Also disclosed are pharmaceutical compositions comprising one or more F12 RNAi initiators and one or more excipients capable of delivering the RNAi initiators to hepatocytes. Delivery of the F12 RNAi initiator to hepatocytes in vivo provides inhibition of F12 gene expression and treatment of angioedema, including hereditary angioedema (HAE), venous thromboembolism (VTE), and diseases associated with angioedema.

The invention discloses a nucleic acid methylation detection method for early screening of liver cancer and a corresponding kit for liver cancer detection. A methylation gene detected by the kit contains an F12 (Coagation factor XII) gene, and a detected sample comprises a tissue sample and a plasma sample.

Monoclonal antibodies that bind, such as specifically bind, blood protein factor XII (FXII) are described. The monoclonal antibodies (including antigen-binding fragments thereof) are capable of forming immune complexes with human (FXII) and inhibiting (FXII) activity, resulting in safe anti-inflammatory and anti-thrombotic effects.

A kit for the determination of the thrombogenic power of human immunoglobulins contained in a biologically acceptable product. Also a process making it possible to determine the thrombogenic power linked to the presence of activated Factor XI and / or activated Factor IX and / or activated Factor XII, and / or activated Factor VII and / or activated Factor X in a sample capable of being administered to humans.

The present invention provides assays for the detection of plasma protease C1 inhibitors (C1-INH) that bind plasma kallikrein, factor XII, or both, and their use to identify enzymes that are pKal-mediated or bradykinin-mediated. Risk of a disorder or use in a subject with a pKal-mediated or bradykinin-mediated disorder. The provided methods allow analysis of patients with plasma kallikrein-mediated angioedema (KMA) or other diseases mediated by pKal that can be used for evaluation and treatment.

The present invention relates to an anti-FXII antibody for use in a method of treating or preventing hereditary angioedema (HAE) in a subject in which said antibody is administered subcutaneously to said subject.

The present invention relates to RNAi agents targeting kallikrein B, plasma (Fletcher factor) 1 (KLKB1) gene, factor XII (Hagemann factor) (F12) gene, or kininogen 1 (KNG1) gene, Such as double-stranded RNAi agents, and methods of using these RNAi agents to inhibit the expression of the KLKB1 gene, F12 gene, and / or KNG1 gene, and to treat patients with hereditary angioedema (HAE) and / or disorders associated with the contact activation pathway tester's method.

The present invention relates to methods of use of RNAi agents, e.g., double stranded RNAi agents, targeting a Factor XII (Hageman Factor (F12) gene, for treating subjects having a contact activation pathway-associated disease, such as a thrombophilia or hereditary angioedema (HAE), methods for preventing at least one symptom in a subject having a contact activation pathway-associated disease, such as a thrombus formation or an angioedema attack, and RNAi agents targeting an F12 gene, for use in the methods of the invention.

This invention relates to compounds of formula (I). The compounds of formula (I) are modulators of Factor XII, specifically Factor XIIa. The compounds are inhibitors of Factor XIIa and may be useful as anticoagulants. The compounds of formula (I) may be used in methods of treatment (or prevention) of blood disorders related to bleeding or coagulation.

The invention relates to an inhibitor of Factor XII (FXII) for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia / reperfusion injury in native or transplant kidneys and / or acute kidney injury, a kit for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia / reperfusion injury in native or transplant kidneys, acute kidney injury, renal fibrosis as a result of rejection of a kidney transplant / allograft, and / or fibrosis of a kidney transplant / allograft as a result of rejection or recurrent underlying disease comprising one inhibitor of Factor XII, and an anti-Factor XII (FXII) antibody or antigen binding fragment thereof for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia / reperfusion injury in native or transplant kidneys and / or acute kidney injury comprising one inhibitor of Factor XII.